TACSTD2 and pachyonychia congenita: Corresponding impact of genetic and epigenetic changes was demonstrated for PC response to therapy (63, 64), extending the value of Trop-2 as a therapy target in PC (33), through the targeting of the Trop-2 activated form by next-generation monoclonal antibodies (34).